.Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GX13_Bilastine.Bilastine .Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GX13_Bilastine.Bilastine| name: | Bilastine |
| ATC code: | S01GX13 | route: | oral |
| n-compartments | 2 |
Bilastine is a second-generation non-sedating antihistamine used for the treatment of allergic rhinoconjunctivitis and urticaria in adults and children over 12 years; it is approved and in clinical use today in Europe and other regions.
Pharmacokinetic parameters in healthy adult volunteers after oral administration of bilastine 20 mg as a single dose, under fasting conditions.
Togawa, M, et al., & Nagashima, H (2016). Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. Clinical drug investigation 36(12) 1011–1021. DOI:10.1007/s40261-016-0447-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27498100
Vozmediano, V, et al., & Rodriguez, M (2019). Model-informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 128 180–192. DOI:10.1016/j.ejps.2018.11.016 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30468868
Novák, Z, et al., & Valiente, R (2016). Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 27(5) 493–498. DOI:10.1111/pai.12555 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26918853